Putney Financial Group LLC Takes Position in Stryker Co. (NYSE:SYK)

Putney Financial Group LLC purchased a new position in shares of Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 811 shares of the medical technology company's stock, valued at approximately $292,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC bought a new position in Stryker during the fourth quarter worth $25,000. Rakuten Securities Inc. increased its position in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after buying an additional 68 shares in the last quarter. Centricity Wealth Management LLC acquired a new position in Stryker during the 4th quarter worth approximately $30,000. BankPlus Trust Department bought a new position in Stryker in the fourth quarter worth approximately $33,000. Finally, Activest Wealth Management bought a new stake in shares of Stryker during the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Price Performance

Stryker stock traded down $1.09 during mid-day trading on Friday, hitting $381.26. 388,535 shares of the company traded hands, compared to its average volume of 1,336,556. The stock has a fifty day moving average price of $368.57 and a 200-day moving average price of $376.25. The stock has a market cap of $145.52 billion, a price-to-earnings ratio of 49.14, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.73 by $0.11. The company had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.50 earnings per share. On average, equities analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker's payout ratio is currently 45.41%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent research reports. Barclays increased their target price on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Sanford C. Bernstein set a $450.00 price objective on shares of Stryker in a report on Monday, May 5th. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research report on Tuesday, March 4th. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. Finally, Citigroup reaffirmed a "buy" rating and set a $455.00 price target (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $427.30.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director now owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 5.20% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.